Amyl Therapeutics is a preclinical-stage biotechnology company based in Liège, Belgium, founded in 2020, developing Pan-Amyloid Immunotherapy (PAI): Fc-fusion biologics that bind the conformational amyloid fold shared by amyloid-β, tau and α-synuclein aggregates. Its lead candidate AMX-003 pairs this pan-amyloid binding with a proprietary brain shuttle and targets neurodegenerative diseases such as Alzheimer's and Parkinson's as well as systemic amyloidosis. Historically backed by investors including Noshaq, Mérieux Equity Partners and Sambrinvest, the company is working toward clinical candidate selection and a first-in-human study around 2028.
1
Round
1
Industry
4
Tags
Sep 1, 2026
Latest raise
Funding activity · 1 round
Sep 1, 2026
EUR 8.3M
Series A
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
